Do you recommend testing for UGT1A1 prior to initiating sacituzimab govitecan for patients with metastatic TNBC to mitigate neutropenia risk?  

The phase I/II study of sacituzumab govitecan (SG) treated patients with various solid tumors and 146 patients had UGT1A1 testing. Let's first look at diarrhea. The overall incidence of grade 3 diarrhea was low (6.8%) and could not be predicted by any of the three haplotypes at the 10 mg/kg dos...

I agree with Dr. @Craig R. Hildreth's excellent response! Having a UGT1A1 mutation or not wouldn't change my management. Most cytotoxic chemotherapies cause diarrhea, and we manage it. The chemotherapy component of sacituzumab govitecan is SN38, a metabolite of irinotecan, which is so notorious fo...